Biotech Stocks CDNA, GRAL and TWST Reach 52-Week Highs on Catalyst-Driven Rally

Several biotech stocks reached 52-week highs on September 24, 2026, as investors responded to regulatory progress, clinical milestones and other company-specific catalysts.

CareDx Inc. (CDNA)

CareDx is a precision medicine company developing treatments and healthcare solutions for transplant patients.

The company’s shares climbed more than 13% during intraday trading to reach a 52-week high of $63.09.

CareDx recently secured Medicare coverage for its AlloSure, AlloMap and AlloSeq molecular-testing systems, which help assess the potential for allograft rejection in transplant recipients. The tests are covered for patients who have undergone kidney, heart or lung transplants. The company also completed its acquisition of Naveris and sold its Lab Products business to Eurobio Scientific.

CareDx reported second-quarter revenue of $132 million, up 52% from the prior year. Full-year 2026 revenue is projected at $490 million to $500 million, well above the $380 million recorded in 2025.

Grail Inc. (GRAL)

Grail develops early-cancer detection tests using next-generation sequencing, large-scale population studies, machine learning and automated software.

Shares of the company rose more than 15% on Thursday, reaching a 52-week high of $126.81.

On Wednesday, the Molecular and Clinical Genetics Devices Panel of the FDA’s Medical Devices Advisory Committee issued a positive recommendation for Grail’s Galieri multi-cancer early detection test. The company expects the FDA to make a premarket approval decision in the coming months.

Adaptive Biotechnologies Corporation (ADPT)

Adaptive Biotechnologies is a commercial-stage biotechnology company developing therapies that harness the adaptive immune system.

Shares gained more than 6% during Thursday trading to establish a new 52-week high of $29.58.

The company operates through two main segments: minimal residual disease (MRD) and Immune Medicine. Its MRD business generated $71.6 million, or 92% of second-quarter revenue.

Last week, the National Comprehensive Cancer Network included Adaptive Biotechnologies’ MRD test in its Clinical Practice Guidelines in Oncology as a recommended option for detecting multiple myeloma at an early stage.

Full-year revenue is forecast at $268 million to $278 million, representing projected growth of 26% to 31%.

Revvity Inc. (RVTY)

Revvity provides health-science solutions that combine artificial intelligence and automation with genomic analysis, diagnostics, omics services and other tools for medical professionals.

The company’s shares reached a 52-week high of $152.26 on Thursday and finished the session up 6%.

Revvity reported second-quarter revenue of $730 million, a pro forma increase of 4%. The company raised its full-year revenue guidance to $2.83 billion-$2.86 billion, reflecting projected pro forma growth of 4% to 5%.

Revvity recently launched its SuperFlex prenatal testing service and expanded coverage for its preeclampsia diagnostics. It is also advancing an automated version of its T-SPOT.TB tuberculosis test for clinical laboratories.

Twist Bioscience Corporation (TWST)

Twist Bioscience develops DNA-based products for applications including oligonucleotide synthesis, gene libraries, antibody discovery and next-generation sequencing.

The company’s shares surged more than 16% on Thursday to reach a 52-week high of $185.22.

Last week, Twist announced a collaboration with Eli Lilly’s TuneLab to support the discovery of new therapeutic antibodies through artificial intelligence and machine learning.

Twist also produces clonal and complex clonal genes, virus controls for liquid biopsies and a range of preparation, fragmentation and diagnostic kits for microbial genetic testing.

Source link